Standout of the week
DG Matrix
Morrisville maker of solid-state power transformers for AI data centers
Closed a $60M Series A led by Engine Ventures.
DG Matrix builds solid-state power transformers, its Interport platform, aimed at the electrical load of AI data centers. It is the largest disclosed Triangle figure here, announced February 18. SEC filings record about $30M sold against the offering so far. The full investor list differs across outlets and needs reconciling before any database attachment; Engine Ventures is the confirmed lead.
What you should know
Micropep filed regulatory submissions in Brazil and Paraguay for Promisin, its peptide-based biofungicide, with United States and European filings planned. Its US operation is at 9 Laboratory Drive in Research Triangle Park.
GreySun Technologies presented GreyBand at the RIoT Accelerator Program XXII founder showcase in Wilson and won one of three $2,000 Wells Fargo awards.
Kevel, the Durham ad-tech company, launched a retail-media partnership with Dollar General and The Trade Desk that unifies onsite and offsite activation, with testing starting in June. The date is April 30, not this week.
Moment
Pendo
Shipped its Novus product agent, and made Fast Company's Most Innovative list.
Pendo's Novus connects to a code repository, maps the product surface, and opens a pull request to install analytics instrumentation, then reviews incoming pull-request diffs against behavioral data with a person approving each step. It is in open beta and free to start. Separately, the Raleigh product-analytics company was named to Fast Company's 2026 Most Innovative Companies list, in the enterprise category, for the breakthrough launch of its agent analytics. Both surfaced this week; the Novus launch dates to March at Pendomonium.
Deep dives
Capital
9 rounds
$239 million across nine rounds, spanning Cycle Labs in December to ReFiBuy in May. The weight is in deeptech and biotech: DG Matrix's $60M for data-center power, Slate Medicines' $130M migraine-therapy launch, and Ten63's strategic financing that brought its total past $45M. Ten63's new increment was not disclosed, so it is not in the total. Several investor lists still need reconciling before any are attached in the database.
Series A
DG Matrix
$60M
of $60M
This tranche: 100% of total round
Lead: Engine Ventures
With: ABB, Mitsubishi Heavy Industries, Sabanci Climate Ventures, Helios Climate Ventures, Fine Structure Ventures, MCJ
Morrisville. Solid-state transformers for AI data centers. SEC Form D records about $30M sold. Engine Ventures led; investor list reconciled in the edition-8 review pass.
Series A
Slate Medicines
$130M
of $130M
This tranche: 100% of total round
Lead: RA Capital Management, Forbion, Foresite Capital
Raleigh. Anti-PACAP antibody for migraine; asset licensed from DartsBio. CEO Gregory Oakes. Co-led by RA Capital, Forbion, and Foresite. A launched-with-financing biotech; the review pass confirmed the Raleigh headquarters in the financing release.
Venture
Ten63 Therapeutics
—
of $45M
This tranche: 0% of total round
Lead: Chugai Venture Fund
With: Gates Foundation, RYSE, K5 Global, Duke Capital Partners, Cape Fear BioCapital, SF Holdings, Black Opal Ventures, Panorama
RTP. Duke and TTIC spinout; AI drug discovery. New increment undisclosed; total funding now past $45M. Gates grant funds an HPV and cervical-cancer program. Mike Dial of Chugai joins the board.
Seed
ReFiBuy.ai
$13.6M
of $13.6M
This tranche: 100% of total round
Lead: NewRoad Capital Partners
With: Ridge Ventures, Silicon Road Ventures, Commerce Ventures, Incubate Fund, VELA Partners, G20 Ventures, Knoll Ventures
Raleigh. Agentic commerce, founded by four ChannelAdvisor alumni including Scot Wingo. Oversubscribed.
Series A
SonoVascular
$6M
Lead: Harbright Ventures
Chapel Hill. First close of a Series A, not a completed round. SonoThrombectomy for venous thromboembolism; a first-in-human study reported 100% clot reduction across 10 DVT patients. Harbright is a Cary, NC fund; Robert Ross joins the board.
Series B
Incyclix Bio
$5M
of $46.3M
This tranche: 11% of total round
Lead: Hatteras Venture Partners
With: Boxer Capital, RA Capital, Eli Lilly, Cape Fear BioCapital, Eshelman Ventures, Pharmacosmos
RTP. A $5M extension to the Series B, bringing the total to $46.25M. INX-315, a CDK2 inhibitor. Kseniya Simpson of Hatteras joins the board.
Series B
Cycle Labs
$9.7M
Lead: First Analysis
With: Cofounders Capital, North Coast Ventures
Raleigh. Enterprise test automation. A Series B-1. SEC Form D records $5.7M sold of a $9.5M offering; reconcile against the $9.7M release figure.
Levee Medical completed an oversubscribed $12.5M financing to support its PMA as the ARID II trial progresses, raised across 130 investors.
Levee MedicalReselute, a Duke-affiliated orthopedic-device company in Durham, recorded $2.391M sold toward a $4M equity offering across 23 investors in an SEC filing.
SEC Form D/AInfrastructure
Two program and product items from this week.